EPS

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

As CFO Mike Santomassimo prepares for the UBS conference, investors seek clarity on Wells Fargo's strategy after its asset cap removal and rate cut impacts.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Facing a sharp drop in 2025 profits and a dividend cut, Finnish asset manager eQ Plc tasks new CEO Jouko Pölönen with a major strategic reboot.

With a challenging year behind them, Hormel's interim leaders will use upcoming events to prove their strategy can restore profitability and win over Wall Street.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Morningstar's $365M CRSP acquisition and extended Vanguard pact positions it to challenge index titans, promising a new era for low-cost investing.

Atlantic International hires veteran CFO Kevin J. Murphy to integrate its massive Circle8 acquisition and navigate a complex financial landscape.

Investors sue Bitdeer, alleging the company misled them about its advanced crypto mining chip's progress, leading to significant stock price declines.

With home health aide costs nearing $78,000 annually, families face a financial maze. Learn key strategies for creating a realistic budget for senior care.

The oil & gas operator is one step from a NYSE listing, promising a 13.5% dividend yield and a major consolidation play in the mature assets market.

The Dutch brewing giant completes its landmark acquisition, gaining iconic brands like Imperial and a vast retail network to fuel its regional growth strategy.

A new initiative from the Center for Educational Innovation aims to tackle the workforce readiness gap with AI, robotics, and teacher leadership training.

With its stock under pressure, Insperity's upcoming Q4 earnings and 2026 outlook will be a critical test of its strategy to combat rising healthcare costs.

Ferguson Wellman projects a fourth year of market growth, defying skeptic fears, while navigating major wealth planning changes from the ‘Tax Act of 2025’.

Investors eye Rockwell Automation's upcoming conference for insights on its software growth, AI integration, and strategy for navigating economic headwinds.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

With surging revenues and a new body contouring system, Apyx Medical heads to the BTIG conference to prove its growth story is here to stay.

Generac's upcoming earnings report will reveal its navigation of a weak outage year while chasing a data center boom. What does it mean for investors?